• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aligos Therapeutics Inc. (Amendment)

    2/14/24 4:37:13 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email
    SC 13G/A 1 p24-0560sc13ga.htm ALIGOS THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Aligos Therapeutics, Inc.

    (Name of Issuer)
     

    Voting Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    01626L105

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 01626L105

    13GAPage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    5,971,426 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    5,971,426 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,971,426 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.2%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of 4,065,235 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants) held by a fund managed by HHLR (as defined in Item 2(a) below) and 1,906,191 shares of Voting Common Stock held by a fund managed by HIM (as defined in Item 2(a) below). HHLR and HIM are under common control and share certain policies, personnel and resources.

     

    CUSIP No. 01626L105

    13GAPage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    5,971,426 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    5,971,426 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,971,426 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.2%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of 4,065,235 shares of Voting Common Stock (including 1,220,554 shares of Voting Common Stock issuable upon the exercise of warrants) held by a fund managed by HHLR and 1,906,191 shares of Voting Common Stock held by a fund managed by HIM. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

    CUSIP No. 01626L105

    13GAPage 4 of 7 Pages

      

    Item 1(a). NAME OF ISSUER:
      The name of the issuer is Aligos Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
      The Company’s principal executive office is located at One Corporate Drive, 2nd Floor, South San Francisco, CA, 94080.

     

    Item 2(a). NAME OF PERSON FILING:
      This Schedule 13G/A is filed by: (i) HHLR Advisors, Ltd., an exempted Cayman Islands company (“HHLR”) and (ii) Hillhouse Investment Management, Ltd, an exempted Cayman Islands company (“HIM”).  The foregoing persons are hereinafter sometimes each referred to as a “Reporting Person” and collectively referred to as the “Reporting Persons.” HHLR acts as the sole investment manager of HHLR Fund, L.P. (“HHLR Fund”).  HHLR is hereby deemed to be the beneficial owner of, and to control the voting and investment power of, the shares of Voting Common Stock (as defined in Item 2(d) below) held by (and underlying warrants held by) HHLR Fund.  HIM acts as the sole management company of Hillhouse Fund IV, L.P. (“HFIV”).  ATI Holdings LLC (“ATI”) is wholly owned by HFIV.  HIM is hereby deemed to be the beneficial owner of, and to control the voting power of, the Voting Common Stock held by ATI.  HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, each of HHLR and HIM reports on this Schedule 13G/A that it has shared voting and dispositive power of the Voting Common Stock beneficially owned by each of HHLR and HIM.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
      The address of the business office of each of the Reporting Persons is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.

     

    Item 2(c). CITIZENSHIP:
      Cayman Islands

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
      Voting Common Stock, par value $0.0001 per share (the “Voting Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
      01626L105

     

     

    CUSIP No. 01626L105

    13GAPage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                  

     

    Item 4. OWNERSHIP:
      The percentage set forth in this Schedule 13G/A is calculated based upon an aggregate of 71,839,510 shares of Voting Common Stock reported to be issued and outstanding as of October 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 2, 2023, and assumes exercise of the warrants reported herein.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
      Not applicable.

     

     

    CUSIP No. 01626L105

    13GAPage 6 of 7 Pages

     

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
      Not applicable.

     

    Item 10. CERTIFICATION:  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 01626L105

    13GAPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATE:  February 14, 2024  
       
    HHLR Advisors, LTD.  
       
       
    /s/ Audrey Woon  
    Name: Audrey Woon  
    Title: Chief Compliance Officer  

     

     

    HILLHOUSE INVESTMENT MANAGEMENT, LTD.  
       
       
    /s/ Audrey Woon  
    Name: Audrey Woon  
    Title: Chief Compliance Officer  

     

    Get the next $ALGS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    8/18/2025$50.00Buy
    H.C. Wainwright
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $ALGS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    8/14/25 11:54:19 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Aligos Therapeutics Inc.

    SCHEDULE 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)

    8/13/25 2:00:06 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    8/12/25 9:00:35 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany. The company and its collaborators' commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new st

    9/3/25 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. A webcast of the on demand presentation will be accessible by visiting the Presentation & Events section on the "Investors" page of Aligos' website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days. About Aligos Aligos Therapeutics, Inc

    9/2/25 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. "I am thrilled to welcome Ramón to the leadership team at Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we th

    8/20/25 8:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Blatt Lawrence

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 5:14:30 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Symons Julian A.

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 5:14:05 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Calhoun Lesley Ann

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 4:41:45 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00

    8/19/24 6:51:07 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously

    1/6/23 9:05:04 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. "I am thrilled to welcome Ramón to the leadership team at Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we th

    8/20/25 8:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

    SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."

    6/18/25 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

    SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. "I am thrilled to welcome Laura to the Aligos team," said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. "Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expe

    5/20/25 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Financials

    Live finance-specific insights

    View All

    Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

    ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig

    9/19/24 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th

    9/18/24 5:00:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

    CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient

    3/10/22 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:57:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:19:11 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 5:03:16 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care